We aimed to evaluate the effect of slow-release (SR) Fampridine on multiple outcome measures reflecting different domains, and to compare the responsiveness of the Six Spot Step Test (SSST) and the Timed 25 Foot Walk (T25FW).
Methods:
For this study 108 participants were included. On day 0 they were tested with the T25FW, the SSST, the 9-Hole Peg Test (9-HPT), the 5 Times Sit-To-Stand test (5-STS) and the Symbol Digit Modalities Test (SDMT). Four weeks of treatment with SR Fampridine 10 mg BID was commenced. Participants were tested again after 26–28 days of treatment.
Results:
Mean changes observed were: SSST −3.4±6.4s (p<0.001), T25FW −1.2±3.7s (p<0.001), 9-HPT −1.2±6.0s (p<0.001), 5- STS −3.4±7.2s (p<0.001) and SDMT 1.4±4.8 a.u. (p=0.003). Change on the SSST differed significantly from T25FW (SSST 17.0±19.6% vs. T25FW 11.2±17.1%, p=0.0013). Some 48.6% were found to have a meaningful change on the SSST compared with 25.7% on the T25FW. The response to treatment with SR Fampridine did not correlate with age, sex, Expanded Disability Status Scale and disease duration.
Conclusion:
SR Fampridine treatment has significant effects on different domains including upper and lower body and cognition. Furthermore, the SSST is more responsive to the effect of SR Fampridine than is the T25FW.
GottbergKEinarssonUYtterbergC. Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County. Mult Scler2006; 12: 605–612.
5.
HobartJLampingDFitzpatrickR. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain2001; 124: 962–973.
6.
HeesenCBohmJReichC. Patient perception of bodily functions in multiple sclerosis: Gait and visual function are the most valuable. Mult Scler2008; 14: 988–991.
7.
GoodmanADBrownTRKruppLB. Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet2009; 373: 732–738.
8.
BostockHSearsTASherrattRM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol1981; 313: 301–315.
9.
HayesKC. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev2004; 10: 295–316.
10.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology1983; 33: 1444–1452.
11.
GoodmanADBrownTREdwardsKR. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol2010; 68: 494–502.
12.
KieseierBCPozzilliC. Assessing walking disability in multiple sclerosis. Mult Scler2012; 18: 914–924.
13.
ThoumiePLamotteDCantalloubeS. Motor determinants of gait in 100 ambulatory patients with multiple sclerosis. Mult Scler2005; 11: 485–491.
14.
BroekmansTGijbelsDEijndeBO. The relationship between upper leg muscle strength and walking capacity in persons with multiple sclerosis. Mult Scler2013; 19: 112–119.
15.
DalgasUSeverinsenKOvergaardK. Relations between 6 minute walking distance and 10 meter walking speed in patients with multiple sclerosis and stroke. Arch Phys Med Rehabil2012; 93: 1167–1172.
16.
NieuwenhuisMMVan TongerenHSorensenPS. The Six Spot Step Test: A new measurement for walking ability in multiple sclerosis. Mult Scler2006; 12: 495–500.
17.
MollerABBibbyBMSkjerbaekAG. Validity and variability of the 5-Repetition Sit-To-Stand test in patients with multiple sclerosis. Disabil Rehabil2012; 34: 2251–2258.
18.
RudickRACutterGBaierM. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology2001; 56: 1324–1330.
19.
RudickRACutterGReingoldS. The Multiple Sclerosis Functional Composite: A new clinical outcome measure for multiple sderosis trials. Mult Scler2002; 8: 359–365.
20.
LordSRMurraySMChapmanKMunroBTiedemannA. Sit-to-stand performance depends on sensation, speed, balance, and psychological status in addition to strength in older people. J Gerontol A Biol Sci Med Sci2002; 57: M539–M543.
21.
McCarthyEKHorvatMAHoltsbergPA. Repeated chair stands as a measure of lower limb strength in sexagenarian women. J Gerontol A Biol Sci Med Sci2004; 59: 1207–1212.
22.
MongYTeoTWNgSS. 5-Repetition Sit-To-Stand test in subjects with chronic stroke: Reliability and validity. Arch Phys Med Rehabil2010; 91: 407–413.
23.
GoodkinDEHertsgaardDSeminaryJ. Upper extremity function in multiple sclerosis: Improving assessment sensitivity with Box-And-Block and Nine-Hole Peg tests. Arch Phys Med Rehabil1988; 69: 850–854.
24.
ParmenterBAWeinstock-GuttmanBGargN. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler2007; 13: 52–57.
25.
Bronnum-HansenHKoch-HenriksenNStenagerE. The Danish Multiple Sclerosis Registry. Scand J Public Health2011; 39: 62–64.
26.
PolmanCHReingoldSCBanwellB. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
27.
KragtJJvan der LindenFANielsenJM. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler2006; 12: 594–598.
28.
HobartJBlightARGoodmanALynnF. Timed 25-foot walk: Direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology2013; 80: 1509–1517.
29.
LiangMHFosselAHLarsonMG. Comparisons of five health status instruments for orthopedic evaluation. Med Care1990; 28: 632–642.
30.
ColemanCISobierajDMMarinucciLN. Minimally important clinical difference of the Timed 25-Foot Walk Test: Results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin2012; 28: 49–56.
31.
StefoskiDDavisFAFitzsimmonsWE. 4-Aminopyridine in multiple sclerosis: Prolonged administration. Neurology1991; 41: 1344–1348.
32.
WhitneySLWrisleyDMMarchettiGF. Clinical measurement of sit-to-stand performance in people with balance disorders: Validity of data for the Five-Times-Sit-to-Stand Test. Physical therapy2005; 85: 1034–1045.
33.
Oxford GriceKVogelKALeV. Adult norms for a commercially available Nine Hole Peg Test for finger dexterity. Am J Occup Ther2003; 57: 570–573.
34.
GoodmanADCohenJACrossA. Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler2007; 13: 357–368.
35.
BlumDMeadorKBitonV. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology2006; 67: 400–406.
36.
SmitsRCEmmenHHBertelsmannFW. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: A pilot study. Neurology1994; 44: 1701–1705.
37.
PolmanCHBertelsmannFWvan LoenenAC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol1994; 51: 292–296.
38.
RavnborgMSorensenPSChristiansenP. Central motor conduction as a measure of disease progression in early multiple sclerosis. Eur J Neurol1995; 1: 233–241.
39.
JensenHBRavnborgMDalgasU. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: A systematic review. Ther Adv Neurol Disord2014; 7: 97–113.
